Debiopharm invests $6M into Immunexpress for sepsis test development

Debiopharm, the Swiss diagnostics and drug conglomerate, committed $6 million in new financing to Immunexpress, a startup focused on developing a late-stage sepsis test. Immunexpress has worked with Debiopharm since June 2012. Its SeptiCyte technology is designed to quantify a number of biomarkers in a patient's immune system to enable quick detection and management of sepsis compared to regular pathogen detection. SeptiCyte converts the data into an objective score that makes everything from earlier diagnosis to assessment of severity both easier and more certain. Immunexpress is based in both Australia and the U.S. Story

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.